BioGaia ABBGLAF 100 Net-Net Working Capital is $0.62 as of Mar. 2026. GuruFocus rates BGLAF with a GF Score™ of 100/100 and a GF Value™ of $12.55 (Fairly Valued). The stock has 5 warning signs investors should review. Among 415 Drug Manufacturers companies, BioGaia AB ranks worse than 78.31% on this metric.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.
BioGaia AB's Net-Net Working Capital for the quarter that ended in Mar. 2026 was $0.62.
The industry rank for BioGaia AB's Net-Net Working Capital or its related term are showing as below:
BGLAF's Price-to-Net-Net-Working-Capital is ranked worse than 78.31% of 415
companies
in the Drug Manufacturers industry
Industry Median: 7.76
vs BGLAF: 21.03
BioGaia AB (OTCPK:BGLAF) Net-Net Working Capital Explanation
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.
BioGaia AB Net-Net Working Capital Related Terms
BioGaia AB Net-Net Working Capital Historical Data
* Premium members only.
The historical data trend for BioGaia AB's Net-Net Working Capital can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BGLAF vs ZTS, UTHR: Net-Net Working Capital Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, BioGaia AB's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioGaia AB Price-to-Net-Net-Working-Capital vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BioGaia AB's Price-to-Net-Net-Working-Capital distribution charts can be found below:
* The bar in red indicates where BioGaia AB's Price-to-Net-Net-Working-Capital falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.
In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
This is a conservative way of estimating the company's value.
What does a Net-Net Working Capital of $0.62 mean?
BioGaia AB (BGLAF) has a Net-Net Working Capital of $0.62 as of Mar. 2026. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on BioGaia AB According to the industry distribution chart, BioGaia AB ranks #325 out of 415 companies in the Drug Manufacturers industry, placing it in the top 78.3%.
Is BioGaia AB's Net-Net Working Capital too high?
BioGaia AB's current Net-Net Working Capital is $0.62. The Drug Manufacturers industry median Net-Net Working Capital is 7.76. BioGaia AB's value of $0.62 is 92% below this industry median. Based on the distribution chart, BioGaia AB ranks #325 out of 415 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, BioGaia AB has a GF Score™ of 100/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioGaia AB's Net-Net Working Capital compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, BioGaia AB ranks #325 out of 415 companies for Net-Net Working Capital. This places BioGaia AB in the lower half of its industry. The industry median Net-Net Working Capital is 7.76. BioGaia AB's value of $0.62 is 92% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net-Net Working Capital for a Drug Manufacturers company?
The median Net-Net Working Capital among Drug Manufacturers companies is 7.76, based on 415 companies in the industry. Companies in the top quartile (top 25%) have a Net-Net Working Capital significantly above this median, while those in the bottom quartile fall well below. However, Net-Net Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioGaia AB's current Net-Net Working Capital of $0.62 is 92% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net-Net Working Capital mean?
A high Net-Net Working Capital can signal that a stock is expensive relative to its fundamentals. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on BioGaia AB For the Drug Manufacturers industry, the median Net-Net Working Capital is 7.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioGaia AB's current Net-Net Working Capital is $0.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGaia AB stock overvalued right now?
Based on GuruFocus' analysis, BioGaia AB (BGLAF) is currently considered Fairly Valued. The stock's GF Value™ is $12.55, compared to a current price of $12.20 — trading 2.8% below its estimated fair value. The current Net-Net Working Capital is $0.62 and 92% below the Drug Manufacturers industry median of 7.76. BioGaia AB's overall GF Score™ is 100/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net-Net Working Capital calculated?
Net-Net Working Capital is calculated from a company's financial statements. For BioGaia AB (BGLAF), the current Net-Net Working Capital is $0.62 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioGaia AB (BGLAF) Overvalued in 2026?
Based on GuruFocus' analysis, BioGaia AB stock appears to be undervalued.
The current stock price of $12.20 is trading 2.8% below its estimated GF Value™ of $12.55.
GuruFocus considers BioGaia AB to be Fairly Valued.
Key valuation signals for BGLAF:
Net-Net Working Capital: $0.62
GF Value™: $12.55 vs. price of $12.20 (2.8% below fair value)
Industry Position: 92% below the Drug Manufacturers median (#325 of 415)
No single metric tells the full story. See the BGLAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions: EMEA, the Americas, and APAC (Asia-Pacific, Australia, and New Zealand).
100GF Score
Get the complete analysis for BGLAF
Net-Net Working Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BGLAF has been successfully added to your 
